1.The Lilly glucagon-like peptide-1 receptor (GLP-1R) agonist (LSN3318839) is a positive allosteric modulator intended to treat type 2 diabetes. This drug candidate has an interesting proposed mechanism as a molecular glue between GLP-1R and GLP peptide, enhancing endogenous peptide activity. The starting point was identified from a 220k [...]
< 1 minute read
Nov. 3, 2021
LSN3318839: a Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonist
LSN3318839
GLP-1R/GLP molecular glue agonist (PAM) oral blood glucose↓, additive w/ sitaglipin from 220k cmpd cell-based screen + PK opt. J. Med. Chem., Mar. 15, 2021 Lilly Research Laboratories, Indianapolis, IN
Loading...
